Drug Trial Radar · NCT07439094
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer. CKD-703 is composed of a c-Met-targeting monoclonal antibody (mAb) coupled to a cytotoxic payload consisting of the anti-microtubule drug monomethyl auristatin E (MMAE); thus, CKD-703 is a novel ADC offering a highly targeted approach with potential improvement of efficacy while reducing off-target effects for patients with NSCLC and other cancers.
Conditions
- Advanced Solid Tumors
- Non-Small Cell Lung Cancer
Interventions
CKD-703Drug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of patients with dose limiting toxicity (DLT)Time frame: first 21-day period of therapy
- Part 2 and Part 3: Object Response Rate (ORR)Time frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gabrail Cancer Center
Ohio City, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.